Berenberg Bank set a €124.00 ($147.62) target price on Bayer (FRA:BAYN) in a research report report published on Tuesday morning. The firm currently has a neutral rating on the healthcare company’s stock.
BAYN has been the subject of several other reports. J P Morgan Chase & Co reiterated a buy rating on shares of Bayer in a report on Tuesday, August 29th. set a €105.00 ($125.00) price target on shares of Bayer and gave the company a neutral rating in a research report on Tuesday, August 29th. Barclays set a €105.00 ($125.00) price target on shares of Bayer and gave the company a sell rating in a research report on Monday, November 6th. Jefferies Group set a €137.00 ($163.10) price target on shares of Bayer and gave the company a buy rating in a research report on Tuesday, August 29th. Finally, Baader Bank set a €120.00 ($142.86) price target on shares of Bayer and gave the company a neutral rating in a research report on Wednesday, September 13th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of €122.19 ($145.46).
Bayer (BAYN) opened at €104.45 ($124.35) on Tuesday. Bayer has a 1-year low of €86.60 ($103.10) and a 1-year high of €123.82 ($147.40).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
What are top analysts saying about Bayer AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bayer AG and related companies.